Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis

Elijah L. Carlson, Vengadeshprabhu Karuppagounder, William J. Pinamont, Natalie K. Yoshioka, Adeel Ahmad, Eric M. Schott, Heather K. Le Bleu, Michael J. Zuscik, Reyad A. Elbarbary, Fadia Kamal

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Osteoarthritis (OA) is a debilitating joint disease characterized by progressive cartilage degeneration, with no available disease-modifying therapy. OA is driven by pathological chondrocyte hypertrophy (CH), the cellular regulators of which are unknown. We have recently reported the therapeutic efficacy of G protein-coupled receptor kinase 2 (GRK2) inhibition in other diseases by recovering protective G protein-coupled receptor (GPCR) signaling. However, the role of GPCR-GRK2 pathway in OA is unknown. Thus, in a surgical OA mouse model, we performed genetic GRK2 deletion in chondrocytes or pharmacological inhibition with the repurposed U.S. Food and Drug Administration (FDA)-approved antidepressant paroxetine. Both GRK2 deletion and inhibition prevented CH, abated OA progression, and promoted cartilage regeneration. Supporting experiments with cultured human OA cartilage confirmed the ability of paroxetine to mitigate CH and cartilage degradation. Our findings present elevated GRK2 signaling in chondrocytes as a driver of CH in OA and identify paroxetine as a disease-modifying drug for OA treatment.

Original languageEnglish (US)
Article numbereaau8491
JournalScience Translational Medicine
Volume13
Issue number580
DOIs
StatePublished - Feb 10 2021

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis'. Together they form a unique fingerprint.

Cite this